BIOR vs. JAN, NNVC, ACST, ENLV, UBX, ONCT, ITRM, FBRX, LSTA, and RNXT
Should you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include JanOne (JAN), NanoViricides (NNVC), Acasti Pharma (ACST), Enlivex Therapeutics (ENLV), Unity Biotechnology (UBX), Oncternal Therapeutics (ONCT), Iterum Therapeutics (ITRM), Forte Biosciences (FBRX), Lisata Therapeutics (LSTA), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical preparations" industry.
JanOne (NASDAQ:JAN) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.
Biora Therapeutics has a consensus price target of $15.00, indicating a potential upside of 1,955.64%. Given JanOne's higher probable upside, analysts plainly believe Biora Therapeutics is more favorable than JanOne.
JanOne has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
JanOne has higher revenue and earnings than Biora Therapeutics.
In the previous week, Biora Therapeutics had 7 more articles in the media than JanOne. MarketBeat recorded 12 mentions for Biora Therapeutics and 5 mentions for JanOne. JanOne's average media sentiment score of -0.03 beat Biora Therapeutics' score of -0.15 indicating that Biora Therapeutics is being referred to more favorably in the news media.
Biora Therapeutics received 5 more outperform votes than JanOne when rated by MarketBeat users.
JanOne's return on equity of 0.00% beat Biora Therapeutics' return on equity.
6.3% of JanOne shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 3.0% of JanOne shares are held by insiders. Comparatively, 51.0% of Biora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Biora Therapeutics beats JanOne on 8 of the 12 factors compared between the two stocks.
Get Biora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biora Therapeutics Competitors List
Related Companies and Tools
